secwatch.observer — SEC 8-K summary
======================================

Issuer:     BALCHEM CORP (BCPC)
CIK:        0000009326
Form:       8-K
Filed at:   2022-06-27T23:59:59+00:00
Accession:  0001140361-22-024070
Event type: m_and_a
Sentiment:  positive
Materiality: 0.80
Item codes: 2.01, 5.07, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Balchem closes $332.5M acquisition of Kappa Bioscience, financed via credit facility and cash
--------------------------------------------------------------------------------

- Purchase price ~NOK 3.3B ($332.5M) includes assumption and repayment of NOK 303.5M ($30.6M) of Kappa debt.
- Seller eligible for earn-out payment in 2024 of up to ~16% of NOK 3.175B based on growth targets.
- Kappa is a leading science-based manufacturer of specialty vitamin K2 for human nutrition.
- At Annual Meeting, shareholders elected three Class 1 directors, ratified RSM US LLP as auditor, and approved executive compensation on advisory basis.
- Acquisition financed through Balchem's existing revolving credit facility and cash on hand.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/9326/000114036122024070/0001140361-22-024070-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/9326/000114036122024070/brhc10039086_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-22-024070

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer